Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.

World journal of gastroenterology - 21 Dec 2012

Kim Suk Bae, Song Il Han, Kim Young Min, Noh Ran, Kang Ha Yan, Lee Hyang Ie, Yang Hyeon Yoong, Kim An Na, Chae Hee Bok, Lee Sae Hwan, Kim Hong Soo, Lee Tae Hee, Kang Young Woo, Lee Eaum Seok, Kim Seok Hyun, Lee Byung Seok, Lee Heon Young

Abstract excerpt

AIM: To evaluate the treatment outcomes of clevudine compared with entecavir in antiviral-naive patients with chronic hepatitis B (CHB). METHODS: We retrospectively analyzed the clinical data of CHB patients treated with clevudine 30 mg/d and compared their clinical outcomes with patients treated with entecavir 0.5 mg/d. The biochemical response, as assessed by serum alanine aminotransferase (ALT) activity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Genotype

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23322992
DOI: 10.3748/wjg.v18.i47.6943
PMCID: PMC3531678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.PMID 23322992Read ↗

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.Semantic proximity Read ↗

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.Semantic proximity Read ↗

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].Semantic proximity Read ↗

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Semantic proximity Read ↗

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Semantic proximity Read ↗

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.